Targets › IL2RA
26 programs from 24 companies in 45 trials: 21 Phase 1, 18 Phase 2, 5 Phase 3, 1 Phase 4; Oncology, Metabolic and endocrine, Immunology; next expected readout Nov 2026.
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. (UniProt, P01589)
Open in Phaseline: the race on IL2RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Children's Hospital | recombinant humanized anti-CD25 monoclonal antibody anti-CD25 monoclonal antibody | IL2RA | Phase 4 | EBV-T/NK LPD | Oct 2029 |
| Nektar Therapeutics | Rezpegaldesleukin (NKTR-358) Pegylated recombinant human interleukin-2 | IL2RA, IL2 | Phase 3 | Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes Mellitus | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Daclizumab (CD25) Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Graft Versus Host Disease | May 2028 |
| CellTrans | Basiliximab Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia | – |
| Dana-Farber Cancer Institute | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Chronic Graft-versus-host Disease; Acute Myeloid Leukemia; Platinum-resistant Ovarian Cancer; Chronic Graft Versus Host Disease | Nov 2026 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Stage IV Colorectal Cancer; Head Neck Tumors; Mesothelioma, Malignant | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection Anti-CD25 monoclonal antibody | IL2RA | Phase 2 | Acute Graft-versus-Host Disease | Dec 2026 |
| SWOG Cancer Research Network | Nogapendekin Alfa (N-803, ALT-803) IL-15/IL-15Rα fusion protein that activates natural killer cells | IL15, IL2RA | Phase 2 | Advanced Lung Non-Small Cell Carcinoma | Jun 2027 |
| Shanxi Bethune Hospital | Recombinant Humanized Anti-CD25 Monoclonal Antibody Anti-CD25 monoclonal antibody | IL2RA | Phase 2 | Acute Myeloid Leukemia | Aug 2027 |
| Memorial Sloan Kettering Cancer Center | NKTR-214 CD25-targeted IL-2 cytokine prodrug | IL2RA | Phase 2 | SARCOMA | Sep 2027 |
| Rongrong Liu | recombinant humanized anti-CD25 monoclonal antibody anti-CD25 monoclonal antibody | IL2RA | Phase 2 | Transfusion Dependent Thalassemia | Sep 2027 |
| M.D. Anderson Cancer Center | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Melanoma; Metastatic Melanoma; Metastatic Malignant Neoplasm in the Lung | Oct 2027 |
| Assistance Publique - Hôpitaux de Paris | Aldesleukin (ILT-101) Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Type 1 Diabetes | Nov 2027 |
| Shanghai Pulmonary Hospital, Shanghai, China | IBI363 PD-1/IL-2α biased agonist | PDCD1, IL2RA | Phase 2 | Unresectable Stage III Non-small Cell Lung Cancer | Jun 2028 |
| Regeneron Pharmaceuticals | REGN10597 PD-1-IL2Ra-IL2 immunotherapy | PDCD1, IL2RA, IL2 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Melanoma | Jun 2028 |
| Vall d'Hebron Institute of Oncology | ANV419 IL-2 receptor agonist analog | IL2RA | Phase 2 | Melanoma | Sep 2029 |
| PolTREG | ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) Ex vivo expanded regulatory T cell therapy | CD4, CD25, IL2RA | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
| Dana-Farber Cancer Institute | CD25hi Treg depleted DLI Donor lymphocyte infusion with CD25-positive regulatory T cell depletion | IL2RA | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| AgonOx | DP CD8 TIL KD Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 1 | HNSCC | Dec 2026 |
| GI Innovation | GI-108 Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein | CD73, IL2RA | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| Synthekine | STK-009 human orthogonal IL-2 cytokine selective for hoRb-expressing CAR-T cells | IL2RA | Phase 1 | Systemic Lupus Erythematosus; CLL/SLL | Apr 2028 |
| Stanford University | Purified regulatory T-cells (Treg) plus CD34+ HSPC Enriched regulatory T-cell graft engineering to reduce GVHD while maintaining graft functi | IL2RA | Phase 1 | Allogeneic Hematopoietic Cell Transplantation (HCT) | May 2028 |
| Stanford University | Donor Hematopoietic Stem Cells and Recipient Tregs Donor CD34+ hematopoietic stem cells combined with recipient regulatory T cells to facilit | CD34, IL2RA | Phase 1 | Glioma of Spinal Cord; Living Donor Kidney Transplantation | Jul 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Interleukin-2 (IL-2) Cytokine to support TIL expansion and activation | IL2RA, IL2RB, IL2RG | Phase 1 | Lymphocytes | Sep 2029 |
| Alexander B Olawaiye, MD | Denileukin Diftitox (E7777) Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent | EEF2, IL2RA, IL2RG, IL2RB | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
| Mural Oncology | Nemvaleukin alfa (ALKS 4230) IL-2 receptor agonist | IL2RA | Phase 1 | Advanced Solid Tumor | – |
Acute Myeloid Leukemia (5) Melanoma (3) Moderate-to-Severe Atopic Dermatitis (2) Type 1 Diabetes Mellitus (2) Advanced Solid Tumor (2) Acute Graft-versus-Host Disease (1) Metastatic Melanoma (1) Metastatic Malignant Neoplasm in the Lung (1) Chronic Graft-versus-host Disease (1) Platinum-resistant Ovarian Cancer (1) Chronic Graft Versus Host Disease (1) Transfusion Dependent Thalassemia (1)
mixed (12), protein or peptide (5), small molecule (4), antibody (3), other (1)
Dana-Farber Cancer Institute (2) Stanford University (2) Institute of Hematology & Blood Diseases Hospital, China (1) M.D. Anderson Cancer Center (1) Vall d'Hebron Institute of Oncology (1) Rongrong Liu (1) Alexander B Olawaiye, MD (1) Nektar Therapeutics (1) Shanxi Bethune Hospital (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) Regeneron Pharmaceuticals (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Mural Oncology (1) Assistance Publique - Hôpitaux de Paris (1) Memorial Sloan Kettering Cancer Center (1) PolTREG (1) SWOG Cancer Research Network (1) H. Lee Moffitt Cancer Center and Research Institute (1) GI Innovation (1) Synthekine (1)
IL2RG (9) IL2RB (9) IL2 (2) PDCD1 (2) EEF2 (1) CD34 (1) CD4 (1) CD25 (1) IL15 (1) CD73 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.